CEMIP作为癌症的一种预后生物标志物：一项荟萃分析和生物信息学分析

CEMIP as a prognostic biomarker for cancers: a meta- and bioinformatic analysis.

作者信息

Chen Huan, Wang Qingting, Liu Jin, Chen Yuqian, Zhang Qianqian, Chai Limin, Wang Yan, Li Danyang, Qiu Yuanjie, Li Manxiang

机构信息

Department of Respiratory & Critical Care Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

出版信息

Expert Rev Mol Diagn. 2022 Dec;22(12):1107-1115. doi: 10.1080/14737159.2022.2168191. Epub 2023 Jan 17.

DOI:10.1080/14737159.2022.2168191

PMID:36631437

Abstract

OBJECTIVE

Cell migration-inducing and hyaluronan-binding protein () is overexpressed in several cancers and is related to prognosis in cancer patients. Here, we conducted a meta-analysis to explore the prognostic effects of in cancer patients.

METHODS

Relevant published studies were systematically searched in four databases. The role of was evaluated using pooled hazard ratios (HRs), odd ratios (ORs), and 95% confidence intervals (95% CIs). The Cancer Genome Atlas (TCGA) was used to investigate the prognostic value of in various cancers.

RESULTS

11 literatures with 1355 patients were included in this meta-analysis. The results showed that overexpression of was significantly associated with poor OS (HR = 3.03; 95% CI: 2.00-4.59; < 0.001), DFS (HR = 3.38; 95% CI: 2.41-4.74; < 0.001). Elevated expression is associated with advanced clinical stage, lymph node metastasis, and poor histological grade. In addition, TCGA datasets were used to verify that was found highly expressed in multiple cancers and was associated with poorer survival.

CONCLUSION

The results demonstrated that could be a novel prognostic biomarker for cancer patients. However, because the included studies mainly focused on Asian populations, further research is needed to verify its applicability.

摘要

目的

细胞迁移诱导与透明质酸结合蛋白（）在多种癌症中过度表达，且与癌症患者的预后相关。在此，我们进行了一项荟萃分析，以探讨其在癌症患者中的预后作用。

方法

在四个数据库中系统检索相关已发表研究。使用合并风险比（HRs）、比值比（ORs）和95%置信区间（95% CIs）评估的作用。利用癌症基因组图谱（TCGA）研究在各种癌症中的预后价值。

结果

本荟萃分析纳入了11篇文献，共1355例患者。结果显示，的过度表达与较差的总生存期（OS）显著相关（HR = 3.03；95% CI：2.00 - 4.59；< 0.001）、无病生存期（DFS）（HR = 3.38；95% CI：2.41 - 4.74；< 0.001）。表达升高与临床晚期、淋巴结转移及较差的组织学分级相关。此外，利用TCGA数据集验证发现其在多种癌症中高表达，并与较差的生存率相关。